Methods, systems and kits for detecting protein-nucleic acid interactions
Methods, systems and kits for detecting protein-nucleic acid interactions, in particular, detecting the genomic location to near-base pair resolution at which a particular protein (e.g., transcription factor) binds includes combining steps of a conventional chromatin immunoprecipitation (ChIP) assay with use of an exonuclease that digests nucleic acid strands in the 5′-3′ or 3′-5′ direction until it reaches a bound protein including a protein crosslinked to the nucleic acid. Proteins that inefficiently crosslink to a nucleic acid and thus are very difficult to detect, are expected to be significantly detected by the kits and methods described herein.
1. A method of identifying a plurality of locations which a protein of interest binds to in a genome, the method comprising the steps of:
(a) subjecting a plurality of cells or extract thereof to a chromatin immunoprecipitation assay using one or more antibodies that specifically bind to a protein of interest and resulting in double-stranded nucleic acid fragments bound to the protein of interest;
(b) subjecting the double-stranded nucleic acid fragments bound to the protein of interest to exonuclease treatment and resulting in single-stranded nucleic acid fragments containing the plurality of locations which the protein of interest binds to, wherein each of the single-stranded nucleic acid fragments has an exonuclease-treated end sequence and the exonuclease treatment is carried out using a double-stranded nucleic acid-specific exonuclease that degrades a nucleic acid in only a 5′-to-3′ or only a 3′-to-5′ direction and a single-stranded nucleic acid-specific exonuclease that degrades a nucleic acid in the same direction as the double-stranded nucleic acid-specific exonuclease;
(c) converting the single-stranded nucleic acid fragments to double-stranded nucleic acid fragments having exonuclease-treated end sequences;
(d) identifying the exonuclease-treated end sequences; and
(e) mapping the plurality of locations which the protein of interest binds to in the genome by identifying the exonuclease-treated end sequences.
2. The method of claim 1 , wherein said identifying the exonuclease-treated end sequences comprises sequencing the double-stranded nucleic acid fragments having exonuclease-treated end sequences.
3. The method of claim 2 , wherein the plurality of locations comprise a majority of locations which the protein of interest binds to.
4. The method of claim 1 , wherein the protein of interest is a protein that binds directly or indirectly to the genome.
5. The method of claim 1 , wherein said identifying the exonuclease-treated end sequences comprises performing at least one method selected from the group consisting of: deoxyribonucleic acid (DNA) sequencing, microarray assay, and polymerase chain reaction (PCR).
6. The method of claim 1 , wherein the genome is selected from the group consisting of: eukaryotic genome, bacterial genome, and viral genome.
7. The method of claim 1 , wherein the single-stranded nucleic acid-specific exonuclease is recJ and the double-stranded nucleic acid-specific exonuclease is lambda exonuclease.
8. The method of claim 1 , wherein each of the plurality of locations is mapped within a resolution of five base pair or less.
9. The method of claim 1 , wherein the genome is a human genome.
10. A method for identifying the nucleotides of a double-stranded nucleic acid sequence to which a peptide or a polypeptide binds, the method comprising the steps of:
(a) obtaining a sample comprising a double-stranded nucleic acid sequence and a peptide or polypeptide;
(b) binding the double-stranded nucleic acid sequence to the peptide or polypeptide, fragmenting the double-stranded nucleic acid sequence and resulting in double-stranded nucleic acid fragments having the peptide or polypeptide bound thereto;
(c) immunoprecipitating the double-stranded nucleic acid fragments using one or more antibodies that specifically bind to the peptide or polypeptide, wherein the double-stranded nucleic acid fragments comprise flanking ends which are capable of being cleaved by exonucleases;
(d) subjecting the double-stranded nucleic acid fragments from step (c) to exonuclease treatment, wherein the exonuclease treatment is carried out using a double-stranded nucleic acid-specific exonuclease that degrades a nucleic acid in only a 5′-to-3′ or only a 3′-to-5′ direction and a single-stranded nucleic acid-specific exonuclease that degrades a nucleic acid in the same direction as the double-stranded nucleic acid-specific exonuclease, and resulting in single-stranded fragment nucleic acid fragments, wherein each of the single-stranded nucleic acid fragments comprises nucleotides that bind to the peptide or polypeptide; and
(e) identifying the nucleotides of the double-stranded nucleic acid sequence to which the peptide or a polypeptide binds by identifying the nucleotides that bind to the peptide or polypeptide in the single-stranded nucleic acid fragments.
11. The method of claim 10 , wherein said identifying the nucleotides that bind to the peptide or polypeptide in the single-stranded nucleic acid fragments further comprises converting the single-stranded nucleic acid fragments to double-stranded nucleic acid fragments comprising nucleotides that bind to the peptide or polypeptide and sequencing the double-stranded nucleic acid fragments comprising nucleotides that bind to the peptide or polypeptide.
12. The method of claim 10 , wherein the double-stranded nucleic acid sequence is a human genome.
13. The method of claim 10 , wherein the double-stranded nucleic acid-specific exonuclease is lambda exonuclease.
14. The method of claim 12 , further comprising mapping a location of the double-stranded nucleic acid sequence to which the peptide or polypeptide binds, and wherein the location is identified with a resolution of five base pairs or less.
15. A method of identifying a plurality of locations which a protein of interest binds to in a genome, the method comprising the steps of:
(a) subjecting a plurality of cells or extract thereof to a chromatin immunoprecipitation assay using one or more antibodies that specifically bind to a protein of interest and resulting in single-stranded nucleic acid fragments bound to the protein of interest;
(b) subjecting the single-stranded nucleic acid fragments bound to the protein of interest to exonuclease treatment and resulting in single-stranded nucleic acid fragments containing the plurality of locations which the protein of interest binds to, wherein each of the single-stranded nucleic acid fragments has an exonuclease-treated end sequence and the exonuclease treatment is carried out using a single-stranded nucleic acid-specific exonuclease that degrades a nucleic acid in only a 5′-to-3′ or only a 3′-to-5′ direction;
(c) converting the single-stranded nucleic acid fragments to double-stranded nucleic acid fragments having exonuclease-treated end sequences;
(d) identifying the exonuclease-treated end sequences; and
(e) mapping the plurality of locations which the protein of interest binds to in the genome by identifying the exonuclease-treated end sequences.
16. The method of claim 15 , wherein said identifying the exonuclease-treated end sequences comprises sequencing the double-stranded nucleic acid fragments having exonuclease-treated end sequences.
17. The method of claim 15 , wherein the protein of interest is a protein that binds directly or indirectly to the genome.
18. The method of claim 15 , wherein said identifying the exonuclease-treated end sequences comprises performing at least one method selected from the group consisting of:
nucleic acid sequencing, microarray assay, and PCR.
19. The method of claim 15 , wherein the genome is selected from the group consisting of: eukaryotic genome, bacterial genome, and viral genome.
20. The method of claim 15 , wherein the single-stranded nucleic acid fragments are ribonucleic acid (RNA).
21. A method for identifying the nucleotides of a single-stranded nucleic acid sequence to which a peptide or a polypeptide binds, the method comprising the steps of:
(a) obtaining a sample comprising a single-stranded nucleic acid sequence and a peptide or polypeptide;
(b) binding the single-stranded nucleic acid sequence to the peptide or polypeptide, fragmenting the single-stranded nucleic acid sequence and resulting in single-stranded nucleic acid fragments having the peptide or polypeptide bound thereto;
(c) immunoprecipitating the single-stranded nucleic acid fragments using one or more antibodies that specifically bind to the peptide or polypeptide, wherein the single-stranded nucleic acid fragments comprise flanking ends which are capable of being cleaved by single-stranded nucleic acid exonucleases;
(d) subjecting the single-stranded nucleic acid fragments to exonuclease treatment, wherein the exonuclease treatment is carried out using a single-stranded nucleic acid-specific exonuclease that degrades a nucleic acid in only a 5′-to-3′ or only a 3′-to-5′ direction;
(e) reversing the binding of the peptide or polypeptide to the single-stranded nucleic acid fragments and converting the single-stranded nucleic acid fragments to double-stranded nucleic acid fragments comprising nucleotides that bind to the peptide or polypeptide; and
(f) identifying the nucleotides of the single-stranded nucleic acid sequence to which the peptide or a polypeptide binds by identifying the nucleotides that bind to the peptide or polypeptide in the double-stranded nucleic acid fragments.
22. The method of claim 21 , wherein the single-stranded nucleic acid sequence is RNA.
23. The method of claim 21 , wherein said identifying the nucleotides that bind to the peptide or polypeptide in the double-stranded nucleic acid fragments comprises sequencing the double-stranded nucleic acid fragments.